Eran Leitersdorf

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1792445/publications.pdf

Version: 2024-02-01

78 papers

7,167 citations

126708 33 h-index 72 g-index

80 all docs

80 docs citations

80 times ranked 8803 citing authors

#	Article	IF	CITATIONS
1	Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. New England Journal of Medicine, 2012, 367, 2089-2099.	13.9	1,754
2	Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism. Circulation, 1998, 98, 2088-2093.	1.6	1,540
3	Atherosclerosis in the Apolipoprotein E–Deficient Mouse. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1006-1014.	1.1	433
4	Markedly Reduced Bile Acid Synthesis but Maintained Levels of Cholesterol and Vitamin D Metabolites in Mice with Disrupted Sterol 27-Hydroxylase Gene. Journal of Biological Chemistry, 1998, 273, 14805-14812.	1.6	230
5	Elimination of Cholesterol in Macrophages and Endothelial Cells by the Sterol 27-Hydroxylase Mechanism. Journal of Biological Chemistry, 1997, 272, 26253-26261.	1.6	216
6	Identification of bile acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X receptor. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 223-228.	3.3	189
7	Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. American Heart Journal, 2009, 158, 896-901.e3.	1.2	184
8	Disruption of the Sterol 27-Hydroxylase Gene in Mice Results in Hepatomegaly and Hypertriglyceridemia. Journal of Biological Chemistry, 2000, 275, 39685-39692.	1.6	181
9	Refinement of Variant Selection for the LDL Cholesterol Genetic Risk Score in the Diagnosis of the Polygenic Form of Clinical Familial Hypercholesterolemia and Replication in Samples from 6 Countries. Clinical Chemistry, 2015, 61, 231-238.	1.5	166
10	Possible Association between Diabetes and Bisphosphonate-Related Jaw Osteonecrosis. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1172-1175.	1.8	162
11	Effects of Initiating Moderate Alcohol Intake on Cardiometabolic Risk in Adults With Type 2 Diabetes. Annals of Internal Medicine, 2015, 163, 569-579.	2.0	151
12	Alcohol Dehydrogenase Polymorphisms Influence Alcohol-Elimination Rates in a Male Jewish Population. Alcoholism: Clinical and Experimental Research, 2004, 28, 10-14.	1.4	132
13	Platelet Factor 4 Enhances the Binding of Oxidized Low-density Lipoprotein to Vascular Wall Cells. Journal of Biological Chemistry, 2003, 278, 6187-6193.	1.6	116
14	Whole exome sequencing of familial hypercholesterolaemia patients negative for <i>LDLR</i> /i>/ <i>APOB</i> /i>/ <i>PCSK9</i> mutations. Journal of Medical Genetics, 2014, 51, 537-544.	1.5	104
15	Sterol-regulatory element-binding protein (SREBP)-2 contributes to polygenic hypercholesterolaemia. Atherosclerosis, 2002, 164, 15-26.	0.4	92
16	A Cholesterol-Lowering Gene Maps to Chromosome 13q. American Journal of Human Genetics, 2000, 66, 157-166.	2.6	91
17	Side Chain Hydroxylations in Bile Acid Biosynthesis Catalyzed by CYP3A Are Markedly Up-regulated in Cyp27 Mice but Not in Cerebrotendinous Xanthomatosis. Journal of Biological Chemistry, 2001, 276, 34579-34585.	1.6	70
18	Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome. JAMA Cardiology, 2018, 3, 164.	3.0	68

#	Article	IF	Citations
19	Human Sterol 27-Hydroxylase (CYP27) Overexpressor Transgenic Mouse Model. Journal of Biological Chemistry, 2002, 277, 34036-34041.	1.6	65
20	27-Hydroxycholesterol impairs neuronal glucose uptake through an IRAP/GLUT4 system dysregulation. Journal of Experimental Medicine, 2017, 214, 699-717.	4.2	64
21	The contribution of candidate genes to the response of plasma lipids and lipoproteins to dietary challenge. Atherosclerosis, 2000, 152, 239-248.	0.4	49
22	Human LDL receptor gene: Hincll polymorphism detected by gene amplification. Nucleic Acids Research, 1988, 16, 7215-7215.	6.5	48
23	The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia. Atherosclerosis, 2006, 185, 97-107.	0.4	47
24	Recent Origin and Spread of a Common Lithuanian Mutation, G197del LDLR, Causing Familial Hypercholesterolemia: Positive Selection Is Not Always Necessary to Account for Disease Incidence among Ashkenazi Jews. American Journal of Human Genetics, 2001, 68, 1172-1188.	2.6	46
25	On the regulatory role of side-chain hydroxylated oxysterols in the brain. Lessons from CYP27A1 transgenic and Cyp27a1 $\hat{a}^{-3}/\hat{a}^{-3}$ mice. Journal of Lipid Research, 2013, 54, 1033-1043.	2.0	45
26	Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: Comparative analysis with a fluvastatin-cholestyramine combination. American Journal of Medicine, 1994, 96, 401-407.	0.6	44
27	Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population. Clinical Pharmacology and Therapeutics, 1999, 65, 275-282.	2.3	44
28	Sterol 27-hydroxylase Deficiency: A Rare Cause of Xanthomas in Normocholesterolemic Humans. Trends in Endocrinology and Metabolism, 2000, 11, 180-183.	3.1	43
29	On the mechanism of accumulation of cholestanol in the brain of mice with a disruption of sterol 27-hydroxylase. Journal of Lipid Research, 2010, 51, 2722-2730.	2.0	43
30	Plasma lipids and lipoproteins response to a dietary challenge: analysis of four candidate genes. Clinical Genetics, 1995, 47, 1-12.	1.0	42
31	CETP genotype and changes in lipid levels in response to weight-loss diet intervention in the POUNDS LOST and DIRECT randomized trials. Journal of Lipid Research, 2015, 56, 713-721.	2.0	39
32	Human LDl receptor gene: two Apali RFLPs. Nucleic Acids Research, 1987, 15, 2782-2782.	6.5	38
33	Shortâ€Term Efficacy and Safety of Extendedâ€Release Fluvastatin in a Large Cohort of Elderly Patients. The American Journal of Geriatric Cardiology, 2003, 12, 225-231.	0.7	33
34	Deep Intronic <i>GBE1</i> Mutation in Manifesting Heterozygous Patients With Adult Polyglucosan Body Disease. JAMA Neurology, 2015, 72, 441.	4.5	33
35	A missense mutation in the low density lipoprotein receptor gene causes familial hypercholesterolemia in Sephardic Jews. Human Genetics, 1993, 91, 141-147.	1.8	32
36	Clinical-biochemical correlation in molecularly characterized patients with Niemann-Pick type C. Genetics in Medicine, 2001, 3, 343-348.	1.1	32

#	Article	IF	CITATIONS
37	Clinical and biochemical features, molecular diagnosis and long-term management of a case of cerebrotendinous xanthomatosis. Clinica Chimica Acta, 2001, 306, 63-69.	0.5	26
38	Hematopoietic overexpression of Cyp27a1 reduces hepatic inflammation independently of 27-hydroxycholesterol levels in Ldlrâ^'/â^' mice. Journal of Hepatology, 2015, 62, 430-436.	1.8	25
39	High-dose fluvastatin and bezafibratecombination treatment for heterozygous familial hypercholesterolemia. American Journal of Cardiology, 1995, 76, 76A-79A.	0.7	24
40	Premature termination codon at the sterol 27-hydroxylase gene causes cerebrotendinous xanthomatosis in a French family. Human Genetics, 1995, 95, 238-40.	1.8	24
41	Hypercholesterolemia in five Israeli Christian-Arab kindreds is caused by the ?Lebanese? allele at the low density lipoprotein receptor gene locus and by an additional independent major factor. Human Genetics, 1991, 88, 75-84.	1.8	23
42	The Relation Between NOD2/CARD15 Mutations and the Prevalence and Phenotypic Heterogeneity of Crohnâ \in TM s Disease: Lessons from the Israeli Arab Crohnâ \in TM s Disease Cohort. Digestive Diseases and Sciences, 2005, 50, 1692-1697.	1.1	23
43	Aplipoprotein E genotyping: accurate, simple, high throughput method using ABI Prism® SNaPshotâ,,¢ Multiplex System. Journal of Alzheimer's Disease, 2004, 6, 497-501.	1.2	22
44	Association Between Cytomegalovirus Infection and Venous Thromboembolism. American Journal of the Medical Sciences, 2007, 334, 111-114.	0.4	21
45	No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels. Atherosclerosis, 2020, 311, 13-19.	0.4	21
46	Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. Diabetes Care, 2020, 43, 1077-1084.	4.3	21
47	Efficacy and safety of triple therapy(fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia. American Journal of Cardiology, 1995, 76, 84A-88A.	0.7	20
48	SREBP-2 and SCAP isoforms and risk of early onset myocardial infarction. Atherosclerosis, 2008, 196, 896-904.	0.4	19
49	Molecular genetics of familial hypercholesterolemia in Israel–revisited. Atherosclerosis, 2017, 257, 55-63.	0.4	19
50	Captopril-Associated Transient Aplastic Anemia. Acta Haematologica, 1985, 73, 106-107.	0.7	18
51	Cerebrotendinous xanthomatosis. Current Opinion in Lipidology, 1994, 5, 138-142.	1.2	18
52	Segregation analysis of plasma lipoprotein(a) levels in pedigrees with molecularly defined familial hypercholesterolemia. Genetic Epidemiology, 1995, 12, 129-143.	0.6	16
53	Identification of two novel LDL receptor gene defects in French-Canadian pediatric population: Mutational analysis and biochemical studies. , 1997, 9, 555-562.		15
54	Impact of different low-density lipoprotein (LDL) receptor mutations on the ability of LDL to support lymphocyte proliferation. Metabolism: Clinical and Experimental, 1999, 48, 834-839.	1.5	15

#	Article	IF	Citations
55	Erythroderma and Pneumonitis Induced by Penicillin?. Respiration, 1986, 50, 301-303.	1.2	14
56	Haplotype analysis at the low density lipoprotein receptor locus: application to the study of familial hypercholesterolemia in Israel. Human Genetics, 1992, 88, 405-410.	1.8	13
57	Influence of apolipoprotein E genotypes on plasma lipid and lipoprotein concentrations: Results from a segregation analysis in pedigrees with molecularly defined familial hypercholesterolemia. , 1996, 13, 159-177.		13
58	Clozapine-Induced Systemic Lupus Erythematosus. Annals of Pharmacotherapy, 2006, 40, 983-985.	0.9	13
59	Absence of familial defective apolipoprotein B-100 in Israeli patients with dominantly inherited hypercholesterolemia and in offspring with parental history of myocardial infarction. Human Genetics, 1993, 91, 299-300.	1.8	12
60	On the regulatory importance of 27-hydroxycholesterol in mouse liver. Journal of Steroid Biochemistry and Molecular Biology, 2017, 169, 10-21.	1,2	11
61	Prenatal diagnosis of familial hypercholesterolemia caused by the ?Lebanese? mutation at the low density lipoprotein receptor locus. Human Genetics, 1992, 89, 237-9.	1.8	10
62	Correlation between coronary artery calcification by non-cardiac CT and Framingham score in young patients. PLoS ONE, 2018, 13, e0195061.	1.1	7
63	Association between statin treatment and LDL-cholesterol levels on the rate of ST-elevation myocardial infarction among patients with acute coronary syndromes: ACS Israeli Survey (ACSIS) 2002–2010. International Journal of Cardiology, 2016, 210, 133-138.	0.8	6
64	Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial. American Heart Journal, 2020, 221, 60-66.	1.2	5
65	HgiAl polymorphism near the HMGCR promoter. Nucleic Acids Research, 1990, 18, 5584-5584.	6.5	4
66	Tongue necrosis and pericarditis. Lancet, The, 2004, 363, 948.	6.3	4
67	Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein. Journal of the American College of Cardiology, 2016, 68, 2488-2490.	1.2	4
68	Cardiovascular risk assessment and treatment to target low density lipoprotein levels in hospitalized ischemic heart disease patients: results of the HOLEM study. Israel Medical Association Journal, 2005, 7, 355-9.	0.1	4
69	Superinduction of the human gene encoding low density lipoprotein receptor. Biochemical and Biophysical Research Communications, 1989, 165, 574-580.	1.0	3
70	The modulation of plasma lipids and lipoproteins during bone marrow transplantation is unrelated to exogenously administered recombinant human granulocyte-mnonocyte colony-stimulating factor (rHu GM-CSF). Medical Oncology, 1996, 13, 81-86.	1.2	3
71	In search of a genetic explanation for LDLc variability in an FH family: common SNPs and a rare mutation in MTTP explain only part of LDL variability in an FH family. Journal of Lipid Research, 2019, 60, 1733-1740.	2.0	2
72	A Tail with a Thorn in it: Second-Generation Antipsychotics Hand in Hand with Statins. Current Atherosclerosis Reports, 2012, 14, 391-393.	2.0	1

#	Article	IF	CITATIONS
73	A rare frameshift mutation in the AGPAT2 gene in a family from gaza with congenital generalized lipodystrophy. Clinical Endocrinology, 2020, 93, 212-214.	1.2	1
74	Anorexia Nervosaâ€"An Unusual Presentation of the Plummer-Vinson Syndrome. International Journal of Psychiatry in Medicine, 1985, 14, 343-346.	0.8	0
75	Shlomo Eisenberg 1935–1995. Atherosclerosis, 1995, 114, 255.	0.4	0
76	Peri-procedural management of antiplatelet therapy, a survey. European Journal of Internal Medicine, 2010, 21, 569-571.	1.0	0
77	Professor Yechezkiel Stein, MD 1926–2015. Atherosclerosis, 2016, 245, 242.	0.4	0
78	Physicians underdiagnose and undertreat obesity in ishemic heart disease patients: data from the HOLEM Study Group. Israel Medical Association Journal, 2006, 8, 553-7.	0.1	0